Back to top

Buy Rating Reaffirmed on Litigation Clarity and Asset Value; $95 Price Target Maintained

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on AnaptysBio and keeping the price target at $95.00. Joseph Pantginis has gi...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AnaptysBio, Inc. (ANAB)